How to buy BioXcel Therapeutics stock

BioXcel Therapeutics, Inc is a biotechnology business based in the US. BioXcel Therapeutics shares (BTAI) are listed on the NASDAQ and all prices are listed in US Dollars. BioXcel Therapeutics employs 50 staff and has a market cap (total outstanding shares value) of 0.00.

BioXcel Therapeutics share price

Use our graph to track the performance of BTAI stocks over time.

BioXcel Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$31.84 - $67.74
50-day moving average	$39.19
200-day moving average	$47.57
Wall St. target price	$102.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.77

Buy BioXcel Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy BioXcel Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of BioXcel Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BioXcel Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-39.57%
Return on equity TTM	-70.35%
Profit margin	0%
Book value	$8.47
Market capitalisation	$846.3 million

TTM: trailing 12 months

Shorting BioXcel Therapeutics shares

There are currently 3.7 million BioXcel Therapeutics shares held short by investors – that's known as BioXcel Therapeutics's "short interest". This figure is 8.9% up from 3.4 million last month.

There are a few different ways that this level of interest in shorting BioXcel Therapeutics shares can be evaluated.

BioXcel Therapeutics's "short interest ratio" (SIR)

BioXcel Therapeutics's "short interest ratio" (SIR) is the quantity of BioXcel Therapeutics shares currently shorted divided by the average quantity of BioXcel Therapeutics shares traded daily (recently around 565252.16718266). BioXcel Therapeutics's SIR currently stands at 6.46. In other words for every 100,000 BioXcel Therapeutics shares traded daily on the market, roughly 6460 shares are currently held short.

However BioXcel Therapeutics's short interest can also be evaluated against the total number of BioXcel Therapeutics shares, or, against the total number of tradable BioXcel Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioXcel Therapeutics's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 BioXcel Therapeutics shares in existence, roughly 150 shares are currently held short) or 0.2455% of the tradable shares (for every 100,000 tradable BioXcel Therapeutics shares, roughly 246 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against BioXcel Therapeutics.

Find out more about how you can short BioXcel Therapeutics stock.

BioXcel Therapeutics share dividends

We're not expecting BioXcel Therapeutics to pay a dividend over the next 12 months.

BioXcel Therapeutics share price volatility

Over the last 12 months, BioXcel Therapeutics's shares have ranged in value from as little as $31.84 up to $67.74. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioXcel Therapeutics's is 1.2129. This would suggest that BioXcel Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

BioXcel Therapeutics overview

BioXcel Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut. .

Frequently asked questions

• What percentage of BioXcel Therapeutics is owned by insiders or institutions?

  Currently 38.701% of BioXcel Therapeutics shares are held by insiders and 55.274% by institutions.

• How many people work for BioXcel Therapeutics?

  Latest data suggests 50 work at BioXcel Therapeutics.

• When does the fiscal year end for BioXcel Therapeutics?

  BioXcel Therapeutics's fiscal year ends in December.

• Where is BioXcel Therapeutics based?

  BioXcel Therapeutics's address is: 555 Long Wharf Drive, New Haven, CT, United States, 06511

• What is BioXcel Therapeutics's ISIN number?

  BioXcel Therapeutics's international securities identification number is: US09075P1057

• What is BioXcel Therapeutics's CUSIP number?

  BioXcel Therapeutics's Committee on Uniform Securities Identification Procedures number is: 09075P105